StockNews.AI
CPRX
StockNews.AI
188 days

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

1. Catalyst Pharmaceuticals to release Q4 and full-year 2024 results on Feb 26, 2025. 2. Conference call planned for Feb 27, 2025, to discuss financial results and updates. 3. Catalyst recognized on Forbes 2025 list as a successful mid-cap company. 4. Company committed to developing therapies for rare diseases and enhancing patient accessibility.

4m saved
Insight
Article

FAQ

Why Neutral?

Upcoming financial results could influence market expectations but are standard events. Similar announcements previously led to no significant price changes.

How important is it?

The quarterly report may reflect on financial performance, affecting investor sentiment.

Why Short Term?

Immediate reactions might occur post-announcement; event is routine for stock performances.

Related Companies

CPRX
CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2024 financial results after the market close on Wednesday, February 26, 2025. Catalyst's management team will host a conference call and webcast on Thursday, February 27, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate: February 27, 2025Time: 8:30 AM ETUS/Canada Dial-in Number: (877) 407-8912International Dial-in Number: (201) 689-8059    The webcast will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on the Catalyst website for at least 30 days following the date of the event. About Catalyst PharmaceuticalsCatalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst, headquartered in Coral Gables, FL, was recognized on the Forbes 2025 list as one of America's most successful mid-cap companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s fastest-growing companies. For more information, please visit Catalyst's website at www.catalystpharma.com.  Forward-Looking Statements This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date. Source: Catalyst Pharmaceuticals, Inc.

Related News